LIPIDS AND EMERGING RISK FACTORS: Edited by Dimitri P. Mikhailidis and Debabrata MukherjeeSemaglutide for weight loss and cardiometabolic risk reduction in overweight/obesityMares, Adriana C.a; Chatterjee, Sauravb,c; Mukherjee, Debabrataa Author Information aDepartment of Internal Medicine, Texas Tech University Health Sciences Center at El Paso, El Paso, Texas bDivision of Cardiovascular Medicine, North Shore-Long Island Jewish Medical Centers, Northwell Health cZucker School of Medicine, New York, New York, USA Correspondence to Debabrata Mukherjee, MD, FACC, Chairman, Department of Internal Medicine; Professor of Internal Medicine, Texas Tech University, 4800 Alberta Avenue, El Paso, TX 79905, USA. Tel: +1 915 215 5223; fax: +1 915 545 6634; e-mail: [email protected] Current Opinion in Cardiology 37(4):p 350-355, July 2022. | DOI: 10.1097/HCO.0000000000000955 Buy Metrics Abstract Purpose of review Cardiovascular disease is the most common cause of morbidity and mortality worldwide, and the risk is heightened in the presence of obesity. We review semaglutide, a drug recently approved for chronic weight management in adults with obesity or who are overweight. Recent findings On 4 June 2021, the US Food and Drug Administration approved semaglutide injection at 2.4 mg once weekly for chronic weight management in adults with obesity or overweight with at least one weight-related condition such as high blood pressure, type 2 diabetes mellitus, or high cholesterol. This subcutaneous injection is the first approved drug for chronic weight management in adults with general obesity or overweight since 2014. The drug is indicated for weight management in patients with a BMI of 27 kg/m2 or greater who have at least one weight-related ailment or in patients with a BMI of 30 kg/m2 or greater. Summary Semaglutide offers adults with obesity or overweight a new treatment in conjunction with a weight management program consisting of reduced calorie diet and increased physical activity. Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.